EcoDrugPlus

Tgf-Beta Receptor Type-1

Ensembl ID : ENSOKIG00005033993
Gene Symbol: LOC109875264
3 Cross references
150 Possible Orthologues:

Tgf-Beta Receptor Type-1

Ensembl ID : ENSOKIG00005032204
Gene Symbol: LOC109899370
3 Cross references
199 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSOKIG00005007758
Gene Symbol: LOC109880013
2 Cross references
199 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSOKIG00005019800
Gene Symbol: WEE1
1 Cross references
142 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSOKIG00005013539
Gene Symbol: WEE1
3 Cross references
142 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSOKIG00005040587
Gene Symbol: YES1
3 Cross references
202 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSOKIG00005017366
Gene Symbol: YES1
3 Cross references
202 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSOKIG00005003235
Gene Symbol: ACHE
1 Cross references
227 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSOKIG00005004324
Gene Symbol: ACHE
1 Cross references
227 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSOKIG00005048016
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSOKIG00005013622
Gene Symbol: ACVR2BA
1 Cross references
187 Possible Orthologues:

Activin Receptor Type-2b

Ensembl ID : ENSOKIG00005050094
Gene Symbol: LOC109899315
3 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).